Probing the Effective Treatment Thresholds for Alteplase in Acute Ischemic Stroke With Regression Discontinuity Designs-Reference-Cited by-同舟云学术

Probing the Effective Treatment Thresholds for Alteplase in Acute Ischemic Stroke With Regression Discontinuity Designs

Published:2020-09-02 Issue: Volume:11 Page:
ISSN:1664-2295
Container-title:Frontiers in Neurology
language:
Short-container-title:Front. Neurol.

Author:

Naidech Andrew M.,Lawlor Patrick N.,Xu Haolin,Fonarow Gregg C.,Xian Ying,Smith Eric E.,Schwamm Lee,Matsouaka Roland,Prabhakaran Shyam,Marinescu Ioana,Kording Konrad P.

Funder

Agency for Healthcare Research and Quality

Publisher

Frontiers Media SA

Subject

Neurology (clinical),Neurology

Reference23 articles.

1. Users' guides to the medical literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect;McAlister;JAMA.,1999

2. Tissue plasminogen activator for acute ischemic stroke;N Engl J Med,1995

3. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke;Clark;JAMA.,1999

4. Combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator in acute ischemic stroke-full dose regimen stroke trial;Adeoye;Stroke.,2015

5. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial;Pancioli;Stroke.,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measuring the active elements of cognitive-behavioral therapies;Behaviour Research and Therapy;2023-08

2. Big Data in Stroke: How to Use Big Data to Make the Next Management Decision;Neurotherapeutics;2023-04

3. Astragalus polysaccharide (APS) exerts protective effect against acute ischemic stroke (AIS) through enhancing M2 micoglia polarization by regulating adenosine triphosphate (ATP)/ purinergic receptor (P2X7R) axis;Bioengineered;2022-02-01